The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.Kimberly-Clark is gambling that it can outlast the Trump administration’s Tylenol-autism warnings. Kenvue has a broader portfolio of brand-name products like Band-Aid and Neutrogena.
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm
Scritto il 03/11/2025